---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-007341"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2023-03-10T23:59:59+00:00"
generated_at: "2026-06-18T05:17:31.253262+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma holds less than 2% of cash at failed SVB; exposure limited

## Summary
- As of March 10, 2023, aTyr holds less than 2% of cash equivalents and investments at SVB.
- Company acknowledges SVB closure and FDIC receivership in SEC filing.
- Remaining >98% of cash is held at other institutions, minimizing direct risk.
- No material financial or operational impact anticipated from SVB failure.
- Disclosure made under Regulation FD on March 10, 2023.

## SEC filing metadata
- accession: 0000950170-23-007341
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2023-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017023007341/0000950170-23-007341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017023007341/life-20230310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-007341
- JSON: https://secwatch.observer/filing/0000950170-23-007341.json
- Plain text: https://secwatch.observer/filing/0000950170-23-007341.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.